Dr. Peter Sadow is an ENT Pathologist at Mass. Eye and Ear and the Director of Head and Neck Pathology at Massachusetts General Hospital, where he directs the Anatomic Pathology residency program and is also a subspecialist in Genitourinary Pathology and a consultant in Endocrine Pathology. With a desire to advance our knowledge of human disease, Dr. Sadow pursued a combined M.D./Ph.D. program at the University of Chicago. There, his doctoral thesis utilized transgenic mouse models with altered thyroid hormone response genes in order to understand the effects of thyroid hormone on human physiology. This desire to understand the pathophysiology of endocrine dysfunction led Dr. Sadow to subsequently pursue clinical training in anatomic pathology at Brigham and Women's Hospital, followed by subspecialty training in endocrine, genitourinary, and head and neck pathology.
His clinical and research interests have continued in endocrine pathology, studying the mechanisms of endocrine carcinogenesis through translational studies involving the proteomics and genomics of endocrine neoplasia, primarily of the thyroid and adrenal glands. His Mass. Eye and Ear research has also involved pediatric laryngeal pathology and lesions of the sinonasal tract.
In addition to his clinical and research interests, Dr. Sadow has a prominent teaching roles at Mass General, Harvard Medical School, and in continuing medical education courses.
Routine evaluation of adult tonsillectomy specimens: Toward establishing a new standard of care. Courville EL, Lew M, Sadow PM. Int J Surg Path. 2011 Aug. 19(4):469-75.
Targeting BRAFV600E with PLX4720 displays potent anti migratory and invasive activity in preclinical thyroid cancer models. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S. Oncologist. 2011. 16(3)296-309. Epub 2011 Feb 25.
A 13 year-old girl with an enlarging neck mass. Misra M, Parangi S, Ross DS, Shailam R, Sadow PM. N Engl J Med. 2010 Dec. 363:2445-2454.
Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. Cleary JM, Sadow PM, Randolph GW, Palmer EL, Lynch TP, Nikiforov YE, Wirth LJ. J Clin Oncol. 2010 Aug 10. 28(23):e390-2.
Absence of BRAF, NRAS, KRAS, HRAS mutations and RET/PTC gene rearrangements distinguishes dominant nodules in hashimoto thyroiditis from papillary thyroid carcinomas. Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nose V. Endocr Pathol. 2010 Jun. 21(2):73-9.
A genome-wide screen for microdeletions reveals disruption of polarity gene components in diverse human cancers. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Ma X-J, Erlander M, Rocco JW, Cohen E, Louis DN, Settleman J, Haber DA. Cancer Res. 2010 Mar. 70(6):2158-64.
Mixed medullary-follicular-derived carcinomas of the thyroid gland. Sadow PM, Hunt JL. Adv Anat Pathol. 2010. Jul:17(4):282-5.
Endocrine Neoplasia. Sadow PM. In: Skarin AT, ed. Atlas of Diagnostic Oncology, Fourth Edition, Elsevier Press. 2010.
Poorly differentiated thyroid carcinoma: A cytological-histological review. Bongiovanni M, Sadow PM, Faquin WC. Adv Anat Pathol. 2009 Sept. 16(5):283-289.
Expression of the microtubule modulator stathmin in benign and malignant pheochromocytomas and paragangliomas. Sadow PM, Rumilla KM, Erickson LA, Lloyd RV. Endocr Pathol. 2008 Summer. 19(2):97-103.